4.7 Article

Mouse model of SARS-CoV-2 reveals inflammatory role of type I interferon signaling

Journal

JOURNAL OF EXPERIMENTAL MEDICINE
Volume 217, Issue 12, Pages -

Publisher

ROCKEFELLER UNIV PRESS
DOI: 10.1084/jem.20201241

Keywords

-

Funding

  1. National Institutes of Health [2T32AI007517-16, T32GM007205, F30CA239444, R37AI041699, AI054359, AI127429, T32AI007019, K08 AI128043]
  2. Women'sHealth Research at Yale Pilot Project Program
  3. Emergent Ventures at the Mercatus Center
  4. G. Harold and Leila Y. Mathers Foundation
  5. Ludwig Family Foundation

Ask authors/readers for more resources

Severe acute respiratory syndrome-coronavirus 2 (SARS-Cov-2) has caused over 13,000,000 cases of coronavirus disease (COVID-19) with a significant fatality rate. Laboratory mice have been the stalwart of therapeutic and vaccine development; however, they do not support infection by SARS-CoV-2 due to the virus's inability to use the mouse orthologue of its human entry receptor angiotensin-converting enzyme 2 (hACE2). While hACE2 transgenic mice support infection and pathogenesis, these mice are currently limited in availability and are restricted to a single genetic background. Here we report the development of a mouse model of SARS-CoV-2 based on adeno-associated virus (AAV)-mediated expression of hACE2. These mice support viral replication and exhibit pathological findings found in COVID-19 patients. Moreover, we show that type I interferons do not control SARS-CoV-2 replication in vivo but are significant drivers of pathological responses. Thus, the AAV-hACE2 mouse model enables rapid deployment for in-depth analysis following robust SARS-CoV-2 infection with authentic patient-derived virus in mice of diverse genetic backgrounds.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available